All In MedTech

FDA Clearance Tracker · P810025-S029

AMVISC & AMVISC PLUS (OPHTHALMIC VISCOSURGICAL DEVICES)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 17, 2012 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P810025-S029
Device name
AMVISC & AMVISC PLUS (OPHTHALMIC VISCOSURGICAL DEVICES)
Applicant location
Irvine, CA
Received
Sep 30, 2010
Decided
Jan 17, 2012
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P810025

Device type

Device class
Class III
Regulation
21 CFR 886.4275
Specialty
Ophthalmology

Every decision under product code LZP

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A MANUFACTURING SITE LOCATED AT ANIKA THERAPEUTICS, INC., IN BEDFORD, MASSACHUSETTS.

Source documents

Other decisions for Bausch & Lomb, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.